Mavrogenis Andreas F, Ruggieri Pietro, Mercuri Mario, Papagelopoulos Panayiotis J
Instituto Ortopedico Rizzoli, Bologna, Italy.
J Surg Orthop Adv. 2011 Summer;20(2):106-11.
This article reviews recent molecular, biologic, therapeutic, and clinical findings in dedifferentiated chondrosarcoma. Dedifferentiated chondrosarcoma is one of the most malignant primary bone tumors characterized by two distinct histopathologic components: a well-differentiated chondral lesion sharply juxtaposed with a high-grade noncartilaginous component. Wide or radical surgical resection is mandatory. High-dose radiation therapy is confined to inaccessible sites and palliation. Chemotherapy is administered whenever the dedifferentiated component is chemosensitive and the patient is in good general condition. Despite this approach, metastases will result in poor survival of these patients.
本文综述了去分化软骨肉瘤近期在分子、生物学、治疗及临床方面的研究发现。去分化软骨肉瘤是最恶性的原发性骨肿瘤之一,其特征为具有两种不同的组织病理学成分:一个分化良好的软骨性病变与一个高级别非软骨性成分紧密相邻。广泛或根治性手术切除是必需的。高剂量放射治疗仅限于无法手术的部位及姑息治疗。只要去分化成分对化疗敏感且患者一般状况良好,就会进行化疗。尽管采取了这种治疗方法,转移仍会导致这些患者的生存率较低。